Compugen added Owkin's K Pro alongside its in-house target discovery AI platform.
Compugen wanted general-purpose AI capability beyond its specialized internal platform without diverting resources from its core. It adopted K Pro with access to MOSAIC spatial data. The page quotes faster data exploration and emergent agentic functionality, and says Owkin recapitulated a published paper on Compugen's own data; no figures are given.
Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.
This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.
Published by Owkin on its own site — read the original case study on owkin.com ↗
Related use cases
- 01Boehringer Ingelheim used Owkin's K Pro multi-omic reports to prioritize targets and find spatially informed patient-selection biomarkers.
- 02Epkin used Owkin's K Pro to map prostaglandin biology and design the Phase 1 strategy for OKN4395.
- 03An oncology pharma used Owkin's K Pro and MOSAIC data to triage bispecific ADC candidates in silico.
- 04Owkin's K Pro Autopilot agent proposed a KRAS G12D drug combination that widened eligible patients from about 10% to 60%.
- 05Cleveland Clinic Abu Dhabi cut cohort assembly from days or weeks to seconds with Owkin's data transformation AI and K Pro.
- 06Owkin's MesoNet model predicts mesothelioma survival from pathology images and could shrink Phase 3 trial sizes.